These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 17628752)

  • 21. A novel mucosal vaccine against foot-and-mouth disease virus induces protection in mice and swine.
    Song H; Wang Z; Zheng D; Fang W; Li Y; Liu Y; Niu Z; Qiu B
    Biotechnol Lett; 2005 Nov; 27(21):1669-74. PubMed ID: 16247672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Construction and immunogenicity of recombinant porcine parvovirus-like particles with somatostatin].
    Zhang X; Zheng Q; Chen J; Xue G; Hou H; Hou J
    Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1057-67. PubMed ID: 21090109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction of a recombinant BHV-1 expressing the VP1 gene of foot and mouth disease virus and its immunogenicity in a rabbit model.
    Ren XG; Xue F; Zhu YM; Tong GZ; Wang YH; Feng JK; Shi HF; Gao YR
    Biotechnol Lett; 2009 Aug; 31(8):1159-65. PubMed ID: 19343503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel bi-functional DNA vaccine expressing VP1 protein and producing antisense RNA targeted to 5'UTR of foot-and-mouth disease virus can induce both rapid inhibitory effect and specific immune response in mice.
    Yang B; Lan X; Li X; Yin X; Li B; Han X; Li Y; Zhang Z; Liu J
    Vaccine; 2008 Oct; 26(43):5477-83. PubMed ID: 18694793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response.
    Cheng G; Zhao X; Yan W; Wang W; Zuo X; Huang K; Liu Y; Chen J; Wang J; Cong W; Liu M; Gao H; Chen J; Lu Y; Zheng Z
    Vaccine; 2007 Jul; 25(28):5199-208. PubMed ID: 17555848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective immune response against foot-and-mouth disease virus challenge in guinea pigs vaccinated with recombinant P1 polyprotein expressed in Pichia pastoris.
    Balamurugan V; Renji R; Venkatesh G; Reddy GR; Nair SP; Ganesh K; Suryanarayana VV
    Arch Virol; 2005 May; 150(5):967-79. PubMed ID: 15662485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth properties and vaccine efficacy of recombinant pseudorabies virus defective in glycoprotein E and thymidine kinase genes.
    Wu CY; Liao CM; Chi JN; Chien MS; Huang C
    J Biotechnol; 2016 Jul; 229():58-64. PubMed ID: 27164258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus.
    Zheng M; Jin N; Zhang H; Jin M; Lu H; Ma M; Li C; Yin G; Wang R; Liu Q
    J Virol Methods; 2006 Sep; 136(1-2):230-7. PubMed ID: 16780963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced immunogenicity of multiple-epitopes of foot-and-mouth disease virus fused with porcine interferon alpha in mice and protective efficacy in guinea pigs and swine.
    Du Y; Li Y; He H; Qi J; Jiang W; Wang X; Tang B; Cao J; Wang X; Jiang P
    J Virol Methods; 2008 Apr; 149(1):144-52. PubMed ID: 18294705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.
    Grubman MJ
    Biologicals; 2005 Dec; 33(4):227-34. PubMed ID: 16289996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A live, attenuated pseudorabies virus strain JS-2012 deleted for gE/gI protects against both classical and emerging strains.
    Tong W; Li G; Liang C; Liu F; Tian Q; Cao Y; Li L; Zheng X; Zheng H; Tong G
    Antiviral Res; 2016 Jun; 130():110-7. PubMed ID: 26946112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18.
    Mingxiao M; Ningyi J; Juan LH; Min Z; Guoshun S; Guangze Z; Huijun L; Xiaowei H; Minglan J; Xu L; Haili M; Yue J; Gefen Y; Kuoshi J
    Antiviral Res; 2007 Oct; 76(1):59-67. PubMed ID: 17606304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune responses of recombinant adenovirus co-expressing VP1 of foot-and-mouth disease virus and porcine interferon alpha in mice and guinea pigs.
    Du Y; Dai J; Li Y; Li C; Qi J; Duan S; Jiang P
    Vet Immunol Immunopathol; 2008 Aug; 124(3-4):274-83. PubMed ID: 18511133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of a triple gene-deleted Chinese Pseudorabies virus variant and its efficacy study as a vaccine candidate on suckling piglets.
    Zhang C; Guo L; Jia X; Wang T; Wang J; Sun Z; Wang L; Li X; Tan F; Tian K
    Vaccine; 2015 May; 33(21):2432-7. PubMed ID: 25865469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production and application of recombinant antibodies to foot-and-mouth disease virus non-structural protein 3ABC.
    Foord AJ; Muller JD; Yu M; Wang LF; Heine HG
    J Immunol Methods; 2007 Apr; 321(1-2):142-51. PubMed ID: 17328909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of immune responses to different foot-and-mouth disease genetically engineered vaccines in guinea pigs.
    Yao Q; Qian P; Huang Q; Cao Y; Chen H
    J Virol Methods; 2008 Jan; 147(1):143-50. PubMed ID: 17963851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of protection levels against pseudorabies virus infection of transgenic mice expressing a soluble form of porcine nectin-1/HveC and vaccinated mice.
    Ono E; Tomioka Y; Taharaguchi S; Cherel P
    Vet Microbiol; 2006 May; 114(3-4):327-30. PubMed ID: 16427216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression of truncated gE gene of pseudorabies virus (PRV) and primary application in differential diagnosis of PRV vaccination and infection].
    Ni JQ; Zhang CL; Tong GZ; Qiu HJ; Wang YF; Tian ZJ
    Sheng Wu Gong Cheng Xue Bao; 2004 Jul; 20(4):526-31. PubMed ID: 15968982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Construction of recombinant yellow fever virus 17D containing 2A fragment as a vaccine vector].
    Xiaowu P; Fu WC; Guo YH; Zhang LS; Xie TP; Xinbin G
    Sheng Wu Gong Cheng Xue Bao; 2006 May; 22(3):492-8. PubMed ID: 16755933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate.
    Mayr GA; Chinsangaram J; Grubman MJ
    Virology; 1999 Oct; 263(2):496-506. PubMed ID: 10544121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.